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Background: Post-traumatic stress disorder (PTSD) is a potentially chronic and disabling 
disorder affecting a significant minority of people exposed to trauma. Various psychological 
treatments have been shown to be effective, but their relative effects are not well 
established. 
Methods: We undertook a systematic review and network meta-analyses of psychological 
interventions for adults with PTSD. Outcomes included PTSD symptom change scores post-
treatment and at 1-4-month follow-up, and remission post-treatment. 
Results: We included 90 trials, 6560 individuals and 22 interventions. Evidence was of 
moderate-to-low quality. Eye movement desensitisation and reprocessing [EMDR] (SMD -
2.07; 95%CrI -2.70 to -1.44), combined somatic/cognitive therapies (SMD -1.69; 95%CrI -
2.66 to -0.73), trauma-focused cognitive behavioural therapy [TF-CBT] (SMD -1.46; 95%CrI -
1.87 to -1.05) and self-help with support (SMD -1.46; 95%CrI -2.33 to -0.59) appeared to be 
most effective in reducing PTSD symptoms post-treatment versus waitlist, followed by non-
TF-CBT, TF-CBT combined with a selective serotonin reuptake inhibitor [SSRI], SSRIs, self-
help without support, and counselling. EMDR and TF-CBT showed sustained effects at 1-4-
month follow-up. EMDR, TF-CBT, self-help with support and counselling improved remission 
rates post-treatment. Results for other interventions were either inconclusive or based on 
limited evidence.  
Conclusions: EMDR and TF-CBT appear to be most effective in reducing symptoms and 
improving remission rates in adults with PTSD. They are also effective in sustaining 
symptom improvements beyond treatment endpoint. Further research needs to explore the 
long-term comparative effectiveness of psychological therapies for adults with PTSD and 





Worldwide, post-traumatic stress disorder (PTSD) has a lifetime prevalence of 3.9% in the 
general population, and 5.6% among those exposed to trauma (Koenen et al., 2017). PTSD 
is associated with substantial levels of disability, poor quality of life and functional 
impairment (Alonso et al., 2004). It is often comorbid with other mental disorders such as 
depression, anxiety, substance abuse (Kessler et al., 1995), and has been associated with 
numerous physical health difficulties, including cardiovascular and metabolic disease 
(Ahmadi et al., 2011).  
 
Several psychological treatments are available for the management of PTSD in adults. 
Trauma-focused cognitive behavioural therapy (TF-CBT) is a broad class of psychological 
interventions that predominantly use trauma-focused cognitive, behavioural or cognitive-
behavioural techniques and exposure approaches to treatment. Although some interventions 
place their main emphasis on exposure and others on cognitive techniques, most use a 
combination. There is considerable overlap in the proposed mechanisms underlying the 
effectiveness of the various versions of TF-CBT. TF-CBT includes therapies such as 
cognitive therapy (CT), cognitive processing therapy (CPT), exposure therapy/prolonged 
exposure, virtual reality exposure therapy, mindfulness-based CT and narrative exposure 
therapy. Other available treatments for PTSD include eye movement desensitisation and 
reprocessing (EMDR), interpersonal psychotherapy, present-centered therapy, self-help 
therapies such as internet-based TF-CBT and expressive writing, counselling, non-TF-CBT, 
which focuses on current symptoms of PTSD without re-visiting the trauma experience, and 
combined somatic/cognitive therapies such as emotional freedom techniques and thought 
field therapy; these are exposure-based therapies with both cognitive and somatic 






A number of systematic reviews and meta-analyses have evaluated the effectiveness of 
psychological treatments for adults with PTSD (Bisson et al., 2013; Cusack et al., 2016; 
Forman-Hoffman et al., 2018; Frost et al., 2014; Gerger et al., 2014; Khan et al., 2018; 
Kuester et al., 2016; Seidler and Wagner, 2006; Sijbrandij et al., 2016; van Emmerik et al., 
2013). Commonly they find most robust evidence for the efficacy of individual TF-CBT and 
EMDR, and some evidence for non-TF-CBT, present-centered therapy and self-help. For 
other interventions (such as combined somatic/cognitive therapies) there has been more 
limited high quality research that did not always meet the inclusion criteria for these reviews, 
and therefore no robust conclusions on their effectiveness could be drawn. One review 
suggested that individual TF-CBT, EMDR and non-TF-CBT are more effective than other 
therapies for PTSD (Bisson et al., 2013). Moreover, there was evidence to suggest 
superiority of EMDR over TF-CBT (Khan et al., 2018). However, these findings were not 
confirmed in another review (Gerger et al., 2014). With the exception of one review (Gerger 
et al., 2014), these analyses have made limited comparisons across a narrow range of 
treatments using standard pairwise meta-analysis to synthesise evidence from randomised 
controlled trials (RCTs). This approach does not allow for the relative effectiveness across all 
treatments to be assessed, unless all possible comparisons have been evaluated in head-to-
head trials. 
 
Network meta-analysis (NMA) is a generalisation of pairwise meta-analysis to data 
structures that include, for example, A versus B, B versus C, and A versus C trials (Lu and 
Ades, 2004). NMA strengthens inferences concerning the relative effect of two treatments by 
including both direct and indirect treatment comparisons. This means that NMA allows 
estimation of the relative effects of treatments that may not have been directly compared in 
RCTs. Simultaneous estimation of all relative effects for any number of treatments is 
possible provided that treatments are connected in a single ‘network of evidence’ - that is, 
every treatment is linked to at least one of the other treatments under assessment through 





The objective of this study was to examine the relative effectiveness of psychological 
treatments for PTSD in adults using NMA techniques. The analyses presented here 
supported the updating of national guidance for PTSD in England (National Institute for 
Health and Care Excellence, 2018a). The guideline was developed by a guideline 
committee, an independent multi-disciplinary group of clinical academics, health 
professionals and service user and carer representatives with expertise and experience in 




A search for RCTs of treatments for people with clinically important post-traumatic stress 
symptoms was conducted in the following databases: MEDLINE, Embase, PsycINFO, 
CINAHL and The Cochrane Library. Databases were searched using relevant medical 
subject headings, free-text terms and a study design filter. The aim of the search was to 
update the evidence included in the previous National Institute for Health and Care 
Excellence (NICE) PTSD guideline, published in 2005. The search was undertaken in 
January/February 2017 with re-runs performed in January 2018. Online Supplementary 
Appendix 1 provides full details of the databases and search terms used. The reference lists 
of all relevant systematic reviews were hand-searched for any additional eligible studies. 
Clinical trial registries (ISRCTN and ClinicalTrials.gov) were also hand-searched to identify 
any relevant unpublished trials and authors were contacted to request study reports (where 
these were not available online). Primary authors of published included studies were also 
contacted to request outcome data where these could not be extracted. 
 
Selection criteria for the systematic review and the network meta-analysis 
A systematic review of psychological, psychosocial and other non-pharmacological 




than one month after a traumatic event was carried out in accordance with the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (Moher et 
al., 2009). Eligible populations included adults with either a diagnosis of PTSD according to 
the Diagnostic and Statistical Manual of Mental Disorders (DSM), the World Health 
Organization (WHO) International Classification of Diseases (ICD) or similar criteria, or with 
the presence of clinically significant PTSD symptoms, as indicated by baseline scores above 
a pre-defined threshold on a validated PTSD symptom scale. If some, but not all, of a study’s 
participants had clinically important PTSD symptoms, the study would be included if at least 
80% of participants had clinically important PTSD symptoms or if disaggregated data only for 
those with PTSD could be extracted from the paper. If less than 80% of the participants had 
clinically important PTSD symptoms, or if disaggregated data only for those with PTSD were 
not available, then the mean baseline PTSD symptom score was used and a study was 
included in the review if this mean was above a pre-defined clinical threshold. Primary 
outcomes for the review included PTSD symptom endpoint or change scores on a validated 
PTSD scale; response to treatment; and recovery or remission defined either as the number 
of people no longer meeting diagnostic criteria for PTSD, or with PTSD symptom scores 
below the threshold on a validated scale. 
 
For quality assurance of study identification, and in accordance with NICE guidance 
(National Institute for Health and Care Excellence, 2014), the titles and abstracts of identified 
studies were screened by two reviewers against inclusion criteria specified in the guideline 
review protocols until a good inter-rater reliability was observed (percentage agreement ⩾ 
90%). Initially, a random 10% of references were double-screened and inter-rater agreement 
was good; therefore, the remaining references were screened by one reviewer. All primary-
level studies included after the first citation scan were acquired in full and re-evaluated for 
eligibility at the time of being entered into a study database (standardised template created 
in Microsoft Excel). At least 10% of data extraction (including data informing the risk of bias 




through discussion between reviewers or the opinion of a third reviewer was sought. Data 
were extracted on study characteristics, intervention details, outcome data, and risk of bias. 
 
For the NMA, we considered only first-line psychological treatments offered to adults with a 
diagnosis of PTSD or clinically important post-traumatic stress symptoms more than three 
months after trauma. Pharmacological and combined psychological and pharmacological 
treatments that were linked in the treatment network were also considered. Hypnotherapy, 
psychosocial interventions (meditation, mindfulness-based stress reduction, supported 
employment, peer and practical support) and physical interventions (exercise, yoga, 
acupuncture, bio-neuro-feedback and repetitive transcranial magnetic stimulation) were not 
included in the analysis as they were not considered to be alternative, first-line treatments for 
the management of PTSD in adults. Relaxation was included as a control intervention that 
provided additional indirect comparisons across interventions of interest.  
 
Interventions in the TF-CBT class were not considered separately according to their type. 
Although the specific interventions that make up a class do not include exactly the same 
content or follow the same manual, they use the same broad approach and there is 
considerable overlap in the proposed mechanisms; the efficacy of interventions within the 
class was therefore considered to be equivalent. Hence, in the analyses presented here, TF-
CBT is considered as an umbrella term and forms one node in the network. For the analyses 
that informed the NICE clinical guideline on PTSD, we divided the TF-CBT class by number 
of sessions and format of delivery and created different nodes in the network according to 
the intensity of TF-CBT, as these differences in resource use comprised practical 
considerations that informed the guideline economic analysis, and, subsequently, practice 
recommendations.  
 
The guideline systematic review included two categories of RCTs: those that compared 




waitlist or another inactive control or active intervention; and those comparing interventions 
added to treatment as usual (TAU) versus TAU alone or versus an inactive control added to 
TAU or versus another active intervention added to TAU. The definition of TAU varied widely 
across studies, including minimum contact comparison, a mixture of psychoeducation and 
supportive counselling, medication, substance misuse treatment, any treatment outside the 
research setting or any treatment except the intervention assessed in the study. To reduce 
heterogeneity attributable to the diversity of TAU across RCTs, comparisons involving TAU 
alone or combined with a control or with an intervention of interest were not included in the 
NMA even if they provided links in the network. 
 
The NMA considered two outcomes: PTSD symptom change scores and remission. Data on 
these outcomes were mostly reported at treatment endpoint. Moreover, a number of studies 
reported data on one or both of these outcomes at 1-4-month follow-up. PTSD symptom 
change scores between baseline and 1-4-month follow-up were adequate to inform a NMA; 
in contrast, remission data at 1-4-month follow-up were very sparse (the network only 
included 10 studies, 7 interventions and 572 participants; the only active intervention that 
had been tested on more than 100 participants was TF-CBT). Beyond 1-4 months of follow-
up, available data were very sparse for both outcomes. Based on the availability of data for 
the two outcomes of interest, three separate NMAs were conducted on the following 
outcomes and time points:  
• PTSD symptom change scores between baseline and treatment endpoint 
• PTSD symptom change scores between baseline and 1-4-month follow-up 
• Remission at treatment endpoint 
 
If both were available in the same study, PTSD symptom change scores derived from self-
rated symptom scales were prioritised over those derived from clinician-rated symptom 




with PTSD, according to the NICE guideline committee. Similarly, intention-to-treat (ITT) 
data, obtained after imputation of missing data, were prioritised over completer data, if both 
were available in the same study.  
 
The guideline study protocol was published on the NICE website during consultation of the 
draft guidance with registered stakeholders 
(https://www.nice.org.uk/guidance/ng116/history). The systematic review protocol and the 
additional inclusion criteria applied for the NMA are provided in online Supplementary 
Appendix 2.  
 
Statistical analysis 
NMAs were conducted within a Bayesian framework using a generalised linear model (GLM) 
approach (Dias et al., 2013a), estimated using Markov Chain Monte Carlo simulation 
techniques implemented in WinBUGS 1.4.3 (Lunn et al., 2000; Spiegelhalter et al., 2003). An 
overview of the approach and methods adopted is provided below. Details of the statistical 
analysis and WinBUGS codes used to synthesise changes in PTSD symptom scores and 
dichotomous remission data are reported in online Supplementary Appendix 3. 
 
For the synthesis of continuous data (changes in PTSD symptom scores), a linear model 
with a normal likelihood and identity link was used (Dias et al., 2018). Because the RCTs 
included in the NMAs used different continuous scales to report change in PTSD symptoms, 
relative effects were expressed in the form of the Standardised Mean Difference (SMD) 
between pairs of interventions. For the synthesis of dichotomous data (remission), a linear 
model with binomial likelihood and logit link was used (Dias et al., 2013a; Dias et al., 2018). 
The output of this analysis was the set of log-odds ratios (LORs) between pairs of 
interventions. The suitability of fixed and random effects models in terms of model fit was 
assessed and compared, and the most suitable model (fixed or random effects) was then 





For each analysis we report posterior mean relative effects (either SMD or LOR) with 95% 
credible intervals (CrI). We also report posterior mean ranks with 95%CrI for every treatment 
tested on at least 100 individuals in each analysis, where a rank of 1 indicates highest 
effectiveness. We only included interventions tested on at least 100 people in the ranking, as 
this was deemed the minimum adequate evidence to draw conclusions on effectiveness. 
Results were interpreted in terms of ‘evidence of effect’, rather than ‘statistical significance’ 
(Pike, 2019), and this was determined based on whether the 95%CrI crossed the line of no 
effect. Although no cut-off points were used in order to judge the magnitude of effect, in 
general a SMD value of 0.2 to 0.3 was deemed to indicate a small effect, a value around 0.5 
a medium effect, and a value of 0.8 and above a large effect (Cohen, 1969). 
 
Inconsistency checks 
A basic assumption of NMA methods is that direct and indirect evidence estimate the same 
parameter, that is, the relative effect between A and B measured directly from an A versus B 
trial is the same as the relative effect between A and B estimated indirectly from A versus C 
and B versus C trials. In other words, it is assumed that there is agreement between the 
direct and indirect evidence informing the treatment contrasts (this has also been termed the 
similarity or transitivity assumption (Mavridis et al., 2015)). Inconsistency arises when there 
is a conflict between direct evidence (from an A versus B trial) and indirect evidence (gained 
from A versus C and B versus C trials) and can only be statistically assessed when there are 
closed loops of evidence on 3 treatments that are informed by at least 3 distinct trials (van 
Valkenhoef et al., 2016). The assumption of consistency between indirect and direct 
evidence was explored by undertaking global inconsistency tests (Dias et al., 2010; Dias et 
al., 2013b) and local tests through node-splitting (Dias et al., 2013b; van Valkenhoef and 
Kuiper, 2016). When evidence of inconsistency was found, studies contributing to loops of 
evidence where there might be inconsistency were checked for data accuracy. Analyses 




was still present following data corrections, no studies were excluded from the analysis, as 
their results could not be considered to be less valid than those of other studies solely 
because of the inconsistency findings; nevertheless, the presence of inconsistency in the 
NMA was highlighted and results were interpreted accordingly. 
 
Details of the methods used to test inconsistency and the WinBUGS codes of the 
inconsistency models are provided in online Supplementary Appendix 4.  
 
Pairwise sub-analyses 
For the purposes of the NICE clinical guideline, a number of sub-analyses of the pairwise 
meta-analyses were considered, including sub-analysis by specific intervention type for the 
TF-CBT comparisons, and sub-analyses by trauma type and multiplicity of index trauma for 
all interventions. It is beyond the scope of this paper to explore all sub-analyses but for 
illustrative purposes, exploratory sub-analyses have been conducted by specific TF-CBT 
intervention, method of analysis (ITT versus modified ITT versus completer) and multiplicity 
of index trauma (single or multiple) for the TF-CBT versus waitlist comparison for the PTSD 
symptom change scores between baseline and treatment endpoint outcome. This 
comparison and outcome were selected as it was the only pairwise meta-analysis with 
sufficient studies to enable meaningful comparison between subgroups. A sub-analysis by 
trauma type was not included because there were almost as many trauma types as studies 
and as such the analysis was not interpretable. 
 
RESULTS 
Studies and treatments 
The systematic literature search identified 715 studies potentially eligible for the systematic 
review, 529 of which were excluded. Ninety-six more studies were excluded as they did not 




inactive controls) that reported one or more outcomes of interest (Figure 1). In 64% of the 
included studies, the study population comprised adults with a diagnosis of PTSD; in the 
remaining 36% of the included studies, the study population consisted of adults with clinically 
significant PTSD symptoms, as indicated by baseline scores above a pre-defined threshold 
on a validated PTSD symptom scale. The characteristics of included studies are reported in 
online Supplementary Appendix 5. A list of excluded studies, with reasons for exclusion, is 
provided in online Supplementary Appendix 6. Online Supplementary Appendix 7 shows the 
full data included in each NMA. 
 
Risk of bias assessment 
All 90 included trials were assessed for risk of bias using the Cochrane risk of bias tool 
(Higgins and Green, 2011). Sequence generation and allocation concealment were 
adequately described in 36 and 29 trials, respectively. All trials were regarded as at high risk 
of bias for lack of participant and provider masking. In 20 studies, a clinician-rated scale was 
used, with assessors being unaware of treatment assignment. In seven trials it was unclear if 
the assessors were blinded, and in 63 studies a self-rated scale was used meaning that 
raters were non-blind but were less likely to have a conflict of interest in terms of detection 
bias. Attrition was high in 11 trials and unclear in 35 studies. However, we favoured ITT 
analysis and, for the remission outcome, we conservatively treated drop-outs as failing to 
remit. Of the studies that reported PTSD symptom change scores, approximately 60% 
reported ITT data, or ITT data were possible to estimate, with the remaining providing 
completer data only. Included trials reported a variety of outcomes. Only nine trials were 
registered on a trials database and reported all listed outcomes. Consequently, most studies 
were judged as being at high or unclear risk of reporting bias. Other potential biases were 
identified in seven studies; these included high risk of bias due to potential conflicts of 
interest or due to methodological limitations not otherwise captured. An overview of the trials’ 





NMA model fit statistics 
In all NMAs, the random effects model provided a better fit over the fixed effect model and fit 
the data well. However, the between-trial standard deviation (SD), which measures the 
heterogeneity of treatment effects estimated by trials within contrasts, was high when 
compared with the size of the intervention effect estimates across all three analyses 
(posterior median SD: 0.93 in the NMA of PTSD changes between baseline and treatment 
endpoint; 0.59 in the NMA of changes in PTSD symptom scores between baseline and 1-4-
month follow-up; 1.05 in the NMA of remission at treatment endpoint). 
 
Details of model fit statistics are provided in online Supplementary Appendix 9. 
 
Inconsistency checks 
No evidence of inconsistency between direct and indirect evidence was found in the NMAs 
of changes in PTSD symptom scores at treatment endpoint and at follow-up. The NMA of 
remission at endpoint showed evidence of inconsistency between pooled direct and indirect 
estimates comparing TF-CBT, EMDR, and self-help without support. Direct effects in these 
comparisons were implausibly large and with very wide 95%CrI (e.g. mean LOR of EMDR 
versus TF-CBT -2.01, 95%CrI -4.01 to -0.01), a finding likely attributable to the small number 
and size of RCTs involved in these comparisons; indirect/NMA estimates for these 
comparisons are therefore likely to be more trustworthy. 
 
Results of inconsistency checks are provided in online Supplementary Appendix 10. 
 
Treatment outcomes 
Results of the three analyses are presented in Tables 1-3, as posterior mean effects with 
95%CrI of each intervention versus waitlist, which served as the reference. In each analysis, 
interventions have been ordered from the most to the least effective, according to their 




randomised to each intervention across RCTs included in each analysis, and the number of 
RCTs that assessed each intervention in each NMA. In each analysis, ranking is provided for 
all interventions tested on at least 100 individuals. 
 
Changes in PTSD symptom scores between baseline and treatment endpoint 
The network of changes in PTSD symptom scores between baseline and treatment endpoint 
was formed by 71 RCTs with 151 arms that assessed 19 interventions tested on a total of 
4,700 participants (Figure 2a). The majority of the evidence was on TF-CBT (N=903 in 29 
trials), followed by self-help without support (N=335 in 11 trials) and EMDR (N=260 in 11 
trials). There was also good- or moderately good-sized evidence on counselling (N=278 in 9 
trials), non-TF-CBT (N=209 in 7 trials), self-help with support (N=198 in 5 trials), combined 
somatic/cognitive therapies (N=237 in 4 trials), selective serotonin reuptake inhibitors 
[SSRIs] (N=166 in 5 trials), psychoeducation (N=152 in 2 trials) and TF-CBT combined with 
SSRIs (N=115 in 3 trials). All other interventions were tested on fewer than 100 participants 
each. Of the 71 trials, 26 recruited participants with a single trauma and 38 recruited 
participants with multiple traumas; the remaining 7 studies did not report this kind of 
information. 
 
For interventions tested on N≥100 each with evidence of effect versus waitlist (i.e. 95%CrI 
that did not cross the line of no effect), the ranking (from the most to the least effective) was 
as follows: EMDR (mean SMD versus waitlist -2.07, 95%CrI -2.70 to -1.44), combined 
somatic/cognitive therapies (mean SMD versus waitlist -1.69, 95%CrI -2.66 to -0.73), TF-
CBT (mean SMD versus waitlist -1.46, 95%CrI -1.87 to -1.05), self-help with support (mean 
SMD versus waitlist -1.46, 95%CrI -2.33 to -0.59), non-TF-CBT (mean SMD versus waitlist -
1.22, 95%CrI -1.95 to -0.49), TF-CBT combined with a SSRI (mean SMD versus waitlist -
1.21, 95%CrI -2.35 to -0.07), SSRIs (mean SMD versus waitlist -1.14, 95%CrI -2.09 to -
0.19), self-help without support (mean SMD versus waitlist -0.91, 95%CrI -1.67 to -0.15) and 




Psychoeducation was the only intervention with an adequate evidence base (N=152) and 
inconclusive effect versus waitlist. Although results suggest a trend towards the superiority of 
EMDR over other active interventions, no evidence of differential effects between EMDR and 
other treatments with a large evidence base was found. Comparisons between active 
treatments suggested differences in effect only between EMDR and counselling (mean SMD 
-1.34, 95%CrI -2.19 to -0.49) and between TF-CBT and counselling (mean SMD -0.73, 
95%CrI -1.37 to -0.09).  
 
Metacognitive therapy (mean SMD -3.04, 95%CrI -5.09 to -0.98) and present-centered 
therapy (mean SMD -1.42, 95%CrI -2.45 to -0.40) also showed large effects versus waitlist 
with 95%CrI that did not cross the zero line; however, these effects were based on a more 
limited evidence base (N=10 and 99, respectively). 
 
Overall, results were characterised by relatively wide 95%CrI around mean effects and 
ranks; for example, TF-CBT mostly ranked between the 2nd and 8th place in different 
iterations of the NMA model. High between-study heterogeneity may have contributed to the 
uncertainty around mean effects. 
 
Changes in PTSD symptom scores between baseline and 1-4-month follow- up 
The network of changes in PTSD symptom scores between baseline and 1-4-month follow-
up included 28 RCTs, 2,315 participants and 15 interventions (Figure 2b). TF-CBT was 
again the intervention with the largest evidence base (N=753 in 13 trials); other interventions 
with moderately good-sized evidence base were counselling (N=205 in 4 trials), non-TF-CBT 
(N=123 in 4 trials), EMDR (N=121 in 4 trials) and psychoeducation (N=183 in 3 trials). All 
other interventions were tested on fewer than 100 participants each. Of the 28 trials, 10 and 
15 recruited participants with a single and multiple trauma, respectively; 3 studies did not 





Of the interventions tested on N≥100 each, only two showed evidence of effect versus 
waitlist: EMDR (mean SMD -1.12, 95%CrI -1.94 to -0.27) and TF-CBT (mean SMD -0.73, 
95%CrI -1.23 to -0.25) (Table 2). Comparison between the two showed no evidence of 
difference in effect (mean SMD -0.39 favouring EMDR, 95%CrI -1.30 to 0.54). Interventions 
with N≥100 but inconclusive effects versus waitlist included psychoeducation, non-TF-CBT 
and counselling. 
 
Of interventions with a limited evidence base (each tested on N<100), couple intervention, 
self-help with support and behavioural therapy also showed evidence of effectiveness 
against waitlist. 
 
This analysis was also characterised by high between-study heterogeneity and uncertainty 
that was reflected in wide 95%CrI around mean effects and rankings across interventions. 
 
Remission at treatment endpoint 
The NMA of remission at treatment endpoint consisted of 34 studies, 2,249 participants and 
16 interventions (Figure 2c). TF-CBT was tested on N=601 participants in 21 trials; other 
interventions with a moderately good-sized evidence base were counselling (N=150 in 6 
trials); EMDR (N=132 in 5 trials); and self-help with support (N=105 in two trials). All other 
interventions were tested on fewer than 100 participants each. Of the 34 trials, 15 and 16 
recruited participants with a single and multiple trauma, respectively; 3 studies did not 
provide any information on participants’ number of previous traumas. 
 
All interventions with an adequate evidence base (N≥100) showed evidence of large effects 
versus waitlist. Their order, from the most to least effective was: EMDR (mean LOR versus 
waitlist 3.38, 95%CrI 2.04 to 4.84), TF-CBT (mean LOR versus waitlist 2.46, 95%CrI 1.79 to 
3.19), self-help with support (mean LOR versus waitlist 1.76, 95%CrI 0.03 to 3.49), and 




active treatments suggested differences in effect only between EMDR and counselling 
(mean LOR 2.04, 95%CrI 0.37 to 3.79) and between TF-CBT and counselling (mean LOR 
1.12, 95%CrI 0.12 to 2.15).  
 
Several interventions with limited evidence (each tested on N<100) showed large effects 
versus waitlist on the remission outcome; these included psychodynamic therapy, non-TF-
CBT, relaxation, IPT and present-centered therapy.  
 
As with previous outcomes, there was uncertainty in the results as suggested by very wide 
95%CrI around mean effects and rankings across all interventions (Table 3). There was also 
very high between-study heterogeneity. 
 
Results between all pairs of treatments examined in the NMAs and also results from indirect 
and, where available, direct (head-to-head) comparisons are reported in online 
Supplementary Appendix 11. For information, results of the NICE guideline analyses are 
shown in online Supplementary Appendix 12. 
 
Pairwise sub-analyses 
Exploratory sub-analyses of the pairwise meta-analysis comparing trauma-focused CBT and 
waitlist for PTSD symptom change scores between baseline and endpoint suggests no 
significant subgroup differences for different specific TF-CBT interventions (including CPT, 
cognitive therapy, prolonged exposure, narrative exposure therapy, brief eclectic 
psychotherapy, and non-branded individual and group CBT). There were also no significant 
subgroup differences between ITT, modified ITT and completer analysis, or for single 
compared to multiple incident index trauma. See online Supplementary Appendix 13 for 






Overview of findings 
This study aimed to identify the relative treatment effects of various psychological treatments 
for PTSD. EMDR, combined somatic/cognitive therapies, TF-CBT and self-help with support 
appeared to have the greatest effects in reducing PTSD symptoms post-treatment, followed 
by non-TF-CBT, combined TF-CBT/SSRIs, SSRIs, self-help without support and counselling. 
No evidence of difference in effect post-treatment was identified between interventions, with 
the exception of EMDR and TF-CBT, both of which were found to be superior to counselling. 
Analysis of follow-up data suggested that EMDR and TF-CBT sustained this effect at 1-4 
months. EMDR, TF-CBT, self-help with support, and counselling were also effective in 
achieving remission from PTSD at treatment endpoint. Results for other interventions were 
either inconclusive or based on limited evidence. 
 
Commonalities across effective psychotherapies for PTSD include psychoeducation, 
imaginal exposure, and cognitive processing, restructuring and/or meaning making 
(Schnyder et al., 2015). Moreover, all treatments found to be effective comprised structured 
therapies, delivered by healthcare professionals who have completed specialist training and 
who have access to regular supervision and undertake appropriate continuing professional 
development (CPD) accreditation. Combined somatic/cognitive therapies are exposure-
based therapies with cognitive and somatic components, thus they share some 
characteristics with the TF-CBT class. All except one of the RCTs on self-help with support 
included in the NMA focused on computerised TF-CBT, consistent with TF-CBT delivered by 
a therapist. On the other hand, of the 13 trials on self-help without support, only 4 focused on 
computerised TF-CBT. Further to the presence or absence of the TF-CBT element in self-
help interventions for PTSD, which may have been the driver of their effectiveness, there is 
evidence that facilitated self-help is more effective than self-help without support in the 






Counselling was found to be amongst the least effective interventions. This can be attributed 
to counselling’s non-directive person-centred approach, which is less likely to help the 
person overcome avoidance (which is one of the criteria for PTSD), and thus less likely to 
reduce PTSD symptoms. However, in 10 out of the 11 RCTs examining counselling across 
the 3 NMAs, counselling served as a control treatment to other active interventions, primarily 
TF-CBT, and therefore it is possible that counselling’s effectiveness has been 
underestimated to some extent, due to researcher allegiance.  
 
Comparison with findings of other reviews 
The results of our analysis are consistent with those of other published reviews, according to 
which TF-CBT interventions and EMDR have the strongest evidence of effectiveness post-
treatment and at short follow-up, both showing highest effects versus inactive controls 
compared with other psychological interventions (Bisson et al., 2013; Cusack et al., 2016; 
Forman-Hoffman et al., 2018). This finding is also in line with five recently published PTSD 
clinical practice guidelines (as compared in Hamblen et al., 2019). Four of these five 
guidelines, including the NICE clinical guideline (International Society for Traumatic Stress 
Studies, 2019; National Institute for Health and Care Excellence, 2018a; Phoenix Australia 
Centre for Posttraumatic Mental Health, 2013; Departments of Veterans Affairs and 
Defense, 2017), make recommendations of equal strength for TF-CBT and EMDR for adults, 
whereas in one guideline (American Psychological Association, 2017) TF-CBT interventions 
are favoured with a strong recommendation while EMDR has been given a moderate rating. 
Conversely, Khan et al. (2018) suggests that EMDR may be more effective than TF-CBT, 
however this finding was not supported by another publication that employed NMA 
techniques (Gerger et al., 2014). The latter review is in agreement with our findings, which 
show no evidence of difference between EMDR and TF-CBT. Further research is needed to 





There is some published evidence suggesting that non-TF-CBT (Bisson et al., 2013), 
present-centered therapy (Frost et al., 2014) and self-help (mainly internet-based TF-CBT 
and expressive writing therapy) (Kuester et al., 2016; Sijbrandij et al., 2016; van Emmerik et 
al., 2013) are also effective options in the treatment of PTSD in adults. There are also 
recommendations for other psychotherapies in recently published clinical PTSD guidelines, 
although there was less consistency than for TF-CBT and EMDR (Hamblen et al., 2019). For 
instance, three of the guidelines included recommendations for non-trauma focused 
psychotherapies (International Society for Traumatic Stress Studies, 2019; Phoenix Australia 
Centre for Posttraumatic Mental Health, 2013; Departments of Veterans Affairs and 
Defense, 2017). This evidence, from both published reviews and clinical guidelines, is in line 
with our findings that suggest that non-TF-CBT, present-centered therapy and self-help (with 
or without support) are effective relative to waitlist for improving PTSD symptoms.  
 
Our findings on the effectiveness of combined somatic/cognitive therapies are consistent 
with results reported in the systematic review by Forman-Hoffman et al. (2014), who carried 
out separate evaluations of the emotional freedom technique and thought field therapy 
(defined in the review as ‘imagery rehearsal therapy’) and found very limited evidence on 
both interventions which, nevertheless, indicated that these might be effective in the 
treatment of PTSD symptoms. 
 
Another published NMA of treatments for adults with PTSD suggested that several 
interventions are effective in the management of PTSD (Gerger et al., 2014). That study 
considered a more limited number of interventions than our analysis, including three types of 
TF-CBT (CBT, CT, exposure therapy) that were assessed separately but also as a TF-CBT 
class, EMDR, stress management (relaxation or biofeedback), supportive therapies 
(comprising psychotherapy placebos and counselling), and other psychological therapies 
(including psychodynamic, client-centered, gestalt and other forms). The authors reported 




EMDR were more effective than stress management and supportive therapies, but no 
difference was observed between TF-CBT and EMDR. The robustness of evidence varied 
considerably between different interventions and between-trial heterogeneity was high. 
These findings are in line with our results. The study considered only PTSD symptom 
severity at end of treatment or at maximum of 1 month post-treatment, whereas our NMAs 
considered PTSD change scores at treatment endpoint and at 1-4-month follow-up and also 
remission at end of treatment. Therefore, our conclusions cover a wider range of 
interventions and outcomes and longer-term effects, where available. 
 
Our findings are also broadly consistent with the results of a NMA of psychological 
interventions in children and young people with PTSD, which suggested that TF-CBT, in 
particular individual forms, was most effective in the management of PTSD in youth, 
whereas EMDR was effective but to a lesser extent; counselling did not appear to be 
effective compared with waitlist. Results in young populations also suggested a large 
positive effect for emotional freedom technique (a form of combined somatic/cognitive 
therapy), but this finding was based on very limited evidence (Mavranezouli et al., 2020). 
 
Overall, our results and conclusions are in agreement with previously published meta-
analyses in this area. Small differences between our study results and those of other studies 
(which, nevertheless, led to very similar conclusions) have potentially arisen from differences 
in inclusion criteria relating to the population (e.g. we included only adult populations while 
some other studies did not apply any age restrictions or considered only children and young 
people with PTSD; we did not restrict to people with a formal diagnosis of PTSD while some 
other studies did), interventions (we used a wider range of interventions compared with other 
reviews and it is also possible that our categorisation into classes is different from that used 
in other studies), comparators (we excluded studies that used TAU as a comparator or as a 
component of an active arm), outcomes (we included continuous PTSD symptom change 




some of the other studies included only continuous data and/or only treatment endpoint 
data) and study characteristics (we included studies with a sample size of at least 10 per 
arm, a criterion not applied in most, if not all, the other reviews), as well as differences in the 
method of analysis (we used NMA techniques whereas the vast majority of the other reviews 
in the area relied on pairwise meta-analysis of head-to-head comparisons). 
 
Strengths and limitations of the analysis 
To our knowledge, this is the first NMA of psychological treatments for adults with PTSD that 
was designed to inform a clinical guideline. The results of our NMAs further informed an 
economic analysis that assessed the cost-effectiveness of psychological interventions for 
adults with PTSD (Mavranezouli et al., under review). NMA techniques enabled evidence 
synthesis from both direct and indirect comparisons between interventions, and allowed 
simultaneous inference on all treatments examined in pairwise trial comparisons while 
respecting randomisation (Caldwell et al., 2005; Lu and Ades, 2004). Inconsistency checks 
found no evidence of inconsistency between direct and indirect estimates in the NMAs of 
changes in PTSD symptoms post-treatment and at follow-up. This finding provides 
reassurance that the included studies were comparable across interventions, although it is 
acknowledged that, in agreement with the findings of other reviews, between-trial 
heterogeneity was high. On the other hand, we detected evidence of inconsistency in the 
NMA of remission post-treatment. However, we found that direct effects in this NMA were 
implausibly large and with very wide 95%CrI due to limitations in the direct evidence; 
therefore indirect/NMA evidence may be more trustworthy for the remission outcome. This 
means that results on this outcome (remission at treatment endpoint) should be treated with 
caution. 
 
Between-trial heterogeneity was high across all analyses. This finding, which is consistent 
with previous reviews (Bisson et al., 2013; Forman-Hoffman et al., 2018; Gerger et al., 




trials considered in our analysis, for example, in terms of the presence of a formal PTSD 
diagnosis, the baseline severity and complexity of PTSD symptoms, the type, extent and 
multiplicity of trauma exposure, the chronicity of symptoms and the presence of comorbidity. 
Moreover, the vast majority of the included studies did not distinguish between PTSD and 
complex PTSD, which ICD-11 (unlike DSM-5) now conceptualises as distinct diagnoses. 
This distinction is supported by evidence (Brewin et al., 2017) but some disagreement about 
the validity of the construct amongst experts remains, as suggested by the discrepancy 
between the two classification systems (ICD-11 and DSM-5). We note that our review was 
undertaken before ICD-11 (and the distinction between PTSD and complex PTSD) was 
released (June 2018). Trials are likely to have varied widely in the proportion of participants 
with complex PTSD; this may have had an impact on the effectiveness of assessed 
interventions in each study and the heterogeneity across studies. Another factor potentially 
contributing to the high between-trial heterogeneity of our NMAs is the variability of 
interventions within each treatment node of the analysis (including different levels of 
intensity), and the difference across study settings, e.g. inpatient versus outpatient. This high 
between-trial heterogeneity may have contributed to the uncertainty in the mean relative 
effects, as reflected in the wide CrI for some comparisons in our analyses, and has limited 
our ability to draw firm conclusions on the relative effectiveness between interventions. 
However it is worth noting that, although exploratory in nature and limited to a single 
pairwise comparison, our sub-group analyses suggest that between-study heterogeneity 
cannot be accounted for solely by differences between specific TF-CBT interventions, based 
on the method of analysis (ITT versus completer), or by the multiplicity of index trauma 
(single versus multiple incident index trauma). This suggests that this heterogeneity is 
complex and further studies employing meta-regression techniques, ideally with access to 






We decided to analyse all TF-CBT interventions together, as a class, because, although they 
do not include exactly the same content or follow the same manual, they use the same 
broad approach; in grouping the interventions into a TF-CBT class we took the view that it is 
the core components of the treatments (e.g. exposure and cognitive restructuring) that make 
them effective. We also took into account that ‘breaking’ the solid evidence base for the TF-
CBT class into smaller, separate pieces of evidence for specific interventions would 
unavoidably thin the evidence base and incur the risk of reducing the robustness of our 
conclusions on the effectiveness of interventions within the TF-CBT class relative to other 
types of treatment. Some reviews (for example Bisson et al., 2013; Khan et al., 2018) have 
followed our approach and have evaluated the overall effects of the TF-CBT class, rather 
than looking at the effects of specific interventions within the TF-CBT class separately. The 
Departments of Veterans Affairs and Defense (2017) guideline also grouped TF-CBT 
interventions together but chose to list the specific treatments for which there was the 
strongest support, which is a similar approach to the one taken by the NICE clinical guideline 
(Hamblen et al. 2019). There is now an emerging number of reviews that have attempted to 
evaluate the effects of distinct interventions within the TF-CBT class (e.g. American 
Psychological Association, 2017; Cusack et al., 2016; Forman-Hoffman et al. 2018), with 
another review assessing the overall effect of the TF-CBT class, and also effects of 
individual forms within TF-CBT class where evidence was adequate to allow sub-group 
analysis (International Society for Traumatic Stress Studies, 2019). These reviews have 
carried out separate evaluations of various TF-CBT interventions such as CPT, CT, 
prolonged exposure and mixed TF-CBT which has elements of different types of CBT. The 
majority of these studies have found evidence on the effectiveness of all interventions within 
the TF-CBT class but none of the studies reported any evidence on differential effects 
between different types of TF-CBT. A previously published NMA in the area (Gerger et al., 
2014), which evaluated CBT, exposure and CT separately and made indirect comparisons 
between them, identified no differences in relative effects. The authors then merged CBT 




difference was found between CBT with focus on cognitions and exposure. These results 
suggest that there may be no difference in the effectiveness of different interventions within 
the TF-CBT class, and supports our decision to consider TF-CBT interventions together, as 
one class, in our analysis. It is worth noting here that our exploratory post-hoc sub-analysis 
by specific TF-CBT intervention for all studies including a waitlist control (see Appendix 13A) 
also suggests no significant sub-group difference between specific TF-CBT intervention 
types. 
 
In our analyses we prioritised self-reported over clinician-rated scale data, where possible, 
as self-reported outcomes were deemed to better capture symptoms experienced by adults 
with PTSD, based on the NICE guideline committee’s expert opinion. This approach is in line 
with a previously published NMA in the same area (Gerger et al., 2014), although other 
reviews have conducted separate analyses for clinician-rated and self-reported outcome 
data (Bisson et al., 2013; Forman-Hoffman et al., 2018), or even prioritised clinician-rated 
outcomes over self-reported ones, where both were available, in the primary analysis 
(International Society for Traumatic Stress Studies, 2019). It is acknowledged that in other 
mental health areas, such as depression, it is recommended that both clinician-rated and 
self-reported outcomes be assessed as they have been shown to capture different aspects 
of treatment outcome (Cuijpers et al., 2010; Uher et al., 2012). A sub-group analysis 
conducted by Gerger et al. (2014) showed that the differences between effect sizes in trials 
reporting self-reported outcomes versus those reporting clinician-rated ones were small and 
non-significant (p=0.58) and within-trial heterogeneity was not affected by inclusion of only 
one type of outcome in the analysis. Therefore, we are confident that our choice of 
prioritising self-reported over clinician-rated outcomes has not had a negative impact on 
results. 
 
In our NMA we did not include TAU, either alone or combined with a control or with an 




trials, so that inclusion of TAU in the networks was expected to considerably increase 
heterogeneity and reduce robustness of the results. Omission of studies that assessed 
interventions alone or combined with TAU versus TAU has limited the evidence base of our 
analyses. However, the number of included studies (which did not include TAU) was higher 
than the number of excluded studies that included TAU; included ‘non-TAU’ studies also 
considered a higher number of participants than the excluded ‘TAU’ studies. Therefore, our 
analyses have considered a significant amount of evidence without introducing 
heterogeneity attributable to the diversity of TAU. 
 
The studies included in the NMAs were subject to risk of bias, in particular selection and 
reporting bias. In none of the studies were participants blinded, which was unavoidable due 
to the nature of the interventions. In most trials assessors were not blinded either. As 
described earlier, self-rated PTSD symptom scores were preferred to clinician-rated ones if 
both were reported in a study, as they were deemed to better capture symptoms 
experienced by people with PTSD. However, self-rated assessment cannot be blinded in 
trials of psychological interventions; on the other hand, raters were less likely to have a 
conflict of interest in terms of detection bias. The quality and limitations of RCTs included in 
the analyses need to be considered when interpreting the results. 
 
For the change in PTSD symptom score outcome we prioritised ITT over completer data 
where possible, nevertheless, for approximately 40% of the studies we used completer data 
as only these were available. An exploratory sub-group analysis of the TF-CBT versus 
waitlist comparison for PTSD symptom change scores between baseline and treatment 
endpoint suggests no statistically significant subgroup difference between the results of 
studies using ITT, modified ITT and completer analysis (see Appendix 13B). This is also 
consistent with a sub-group analysis conducted in the context of a NMA of treatments for 
PTSD by Gerger et al. (2014) that showed that the differences between effect sizes in trials 




(p=0.47), although within-trial heterogeneity was somewhat reduced by inclusion of ITT data 
only (from τ2=0.30 when both ITT and completer data were included in the analysis it fell at 
τ2=0.21 when only ITT data were analysed). Our ITT approach for the dichotomous 
remission analysis meant that all participants were analysed in the group to which they had 
been randomised and that study non-completers were assumed to have failed to remit. This 
strategy provides a conservative estimate of treatment effects compared with completer 
analysis (Nüesch et al., 2009), assuming that active interventions have a higher risk of drop-
out compared with control conditions (this higher risk could be attributable to side effects, 
unacceptability of the active intervention, or to people discontinuing treatment early if their 
symptoms improve). 
 
Evidence on the longer-term effectiveness of treatments for PTSD is limited, as follow-up 
data are sparse. Adequate evidence on remission rates at 1-4-month follow-up was only 
available for TF-CBT; for this reason we were not able to conduct any meaningful NMA of 
remission follow-up data. Available evidence suggests that TF-CBT and EMDR are effective 
in sustaining improvements in PTSD symptoms at 1-4-month follow-up. Evidence for other 
interventions was limited or inconclusive. 
 
Implications for practice and need for further research 
Results support current clinical practice within which TF-CBT and EMDR are the mainstream 
options offered to adults with PTSD. Our findings suggest that other treatments, such as 
supported self-help, combined somatic/cognitive therapies and non-TF-CBT are also 
effective and could be potential alternative treatment options, although amongst them only 
supported self-help has some limited evidence for sustained effects beyond treatment. This 
might have implications for clinical practice as services currently focus on provision of TF-
CBT and EMDR. In contrast, although effective versus waitlist, counselling appears to be 
less effective than other treatment options and therefore should not be routinely offered if 




PTSD, which is currently less likely to be identified and managed effectively in routine 
practice. Further research is therefore needed to identify appropriate interventions specific to 
populations with complex PTSD.  
 
Based on the results of the NMAs and the primary economic analysis (Mavranezouli et al., 
under review; National Institute for Health and Care Excellence, 2018b), the NICE guideline 
on PTSD recommended EMDR and individual TF-CBT for the treatment of adults with PTSD 
presenting more than three months after trauma (National Institute for Health and Care 
Excellence, 2018a). Both interventions were effective in reducing PTSD symptoms post-
treatment and demonstrated sufficient evidence to suggest sustainment of effect beyond 
treatment. The recommendation for EMDR was restricted to people with non-combat-related 
trauma, as evidence from sub-group pairwise meta-analysis suggested a non-significant 
effect on people with combat-related trauma, a finding that was confirmed by a recent 
systematic review and meta-analysis (Kitchiner et al., 2019). 
 
In addition, based on the available evidence and after taking account of the narrower 
evidence base, a weaker (‘consider’) recommendation was made for self-help with support 
and SSRIs for people who expressed a preference for these interventions, and, in the case 
of self-help, did not have severe PTSD symptoms and were not at risk of harm to 
themselves or others. A ‘consider’ recommendation was also made for non-TF-CBT targeted 
at specific symptoms, for people who are unable or unwilling to engage in a trauma-focused 
intervention or have residual symptoms after treatment. Finally, the guideline committee 
noted the positive evidence for combined somatic/cognitive therapies, but also considered 
their particularly limited evidence base beyond treatment endpoint and the lack of specific 
indications for these interventions, and decided not to recommend them but instead to make 





TF-CBT was the treatment with the largest evidence base on PTSD symptom severity and 
remission, both at the end of treatment and at 1-4-month follow-up. Further research is 
needed to establish the results for EMDR more firmly, in particular in relation to TF-CBT, as 
conclusions on its effectiveness are based on a more limited evidence base compared with 
TF-CBT and its relative effects versus TF-CBT were characterised by uncertainty. Similarly, 
research should further explore the effectiveness of other interventions, especially combined 
somatic/cognitive therapies, which demonstrated high effects at treatment endpoint, but also 
non-TF-CBT and self-help with support regarding remission and effectiveness beyond end of 
treatment, as relevant evidence is limited or lacking. Future research should also establish 
the effects of different types of TF-CBT relative to other types of treatment, but also relative 
to other types of TF-CBT, as evidence on comparative effectiveness is limited for some 
types of TF-CBT. In particular, evidence on sustainability of effects beyond treatment 
endpoint is sparse and only available for a few treatments; this lack of evidence is most 
evident for remission rates beyond treatment endpoint. This gap in evidence needs to be 
addressed by future trials, which should ideally include at least 12 months of follow-up, to 
explore the longer-term effectiveness of psychological therapies for PTSD.    
 
CONCLUSION 
EMDR and TF-CBT appear to be most effective in reducing symptoms and improving 
remission rates in adults with PTSD. They also appear to be effective in sustaining the 
reduction of PTSD symptoms beyond treatment endpoint. Other interventions, such as 
combined somatic/cognitive therapies, self-help, non-TF-CBT, SSRIs and counselling 
appear to be effective in reducing PTSD symptoms post-treatment; self-help with support 
and counselling appear to improve remission rates post-treatment, too. Counselling is likely 
to be less effective than EMDR and TF-CBT. Further research is needed to establish these 
findings for EMDR, as its evidence base is more limited compared with TF-CBT, and to 
better assess the relative effectiveness of interventions such as different types of TF-CBT, 




regarding remission rates and effectiveness beyond end of treatment. Overall, there is a 
need for well-conducted RCTs to explore the long-term comparative effectiveness of 
psychological therapies for adults with PTSD. 
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Table 1. Network meta-analysis of psychological treatments for PTSD in adults, changes in PTSD symptom scores between baseline 
and treatment endpoint: interventions, magnitude of evidence base and results 
Changes in PTSD symptom scores between baseline and treatment endpoint 
N total = 4700; k total = 71; 151 study arms 
Intervention N k Mean SMD (95%CrI) vs waitlist Mean rank (95%CrI) 
Metacognitive therapy 10 1 -3.04 (-5.09 to -0.98)  
Couple intervention 22 1 -2.67 (-5.41 to 0.06)  
EMDR 260 11 -2.07 (-2.70 to -1.44) 1.78 (1 to 5) 
Combined somatic/cognitive therapies 237 4 -1.69 (-2.66 to -0.73) 3.64 (1 to 9) 
Resilience-oriented treatment 20 1 -1.63 (-3.59 to 0.32)  
TF-CBT 903 29 -1.46 (-1.87 to -1.05) 4.51 (2 to 8) 
Self-help with support 198 5 -1.46 (-2.33 to -0.59) 4.72 (1 to 10) 
Present-centered therapy 99 3 -1.42 (-2.45 to -0.40)  
non-TF-CBT 209 7 -1.22 (-1.95 to -0.49) 6.07 (2 to 10) 
TF-CBT + SSRI 115 3 -1.21 (-2.35 to -0.07) 6.14 (1 to 11) 
Psychoeducation 152 2 -1.21 (-3.13 to 0.71) 6.19 (1 to 12) 
IPT 55 2 -1.19 (-2.54 to 0.15)  
SSRI 166 5 -1.14 (-2.09 to -0.19) 6.55 (2 to 11) 
Self-help without support 335 11 -0.91 (-1.67 to -0.15) 7.77 (3 to 11) 
Relaxation 25 2 -0.73 (-2.15 to 0.70)  
Counselling 278 9 -0.73 (-1.41 to -0.05)  
Attention placebo 221 9 -0.39 (-1.42 to 0.63) 10.12 (5 to 12) 
Waitlist 1312 43 Reference 11.61 (10 to 12) 
Attention bias modification 83 3 2.14 (0.63 to 3.65)  
CrI: credible intervals; EMDR: eye movement desensitisation reprocessing; IPT: interpersonal psychotherapy; SMD: standardised mean 
difference; SSRI: selective serotonin reuptake inhibitor; TF-CBT: trauma-focused cognitive behavioural therapy 




Negative values indicate a better effect for the intervention compared with the reference treatment (waitlist). 
Only interventions tested on at least 100 people were considered in ranking 







Table 2. Network meta-analysis of psychological treatments for PTSD in adults, changes in PTSD symptom scores between baseline 
and 1-4-month follow-up: interventions, magnitude of evidence base and results 
Changes in PTSD symptom scores between baseline and 1-4-month follow-up 
N total = 2,315; k total = 28; 57 study arms 
Intervention N K Mean SMD (95%CrI) vs waitlist Mean rank (95%CrI) 
Couple intervention 21 1 -2.04 (-3.72 to -0.36)  
Self-help with support 85 3 -1.27 (-2.12 to -0.42)  
Self-help without support 40 2 -1.19 (-2.52 to 0.13)  
Behavioural therapy 47 2 -1.19 (-2.16 to -0.21)  
Combined somatic/cognitive therapies 23 1 -1.17 (-2.75 to 0.43)  
EMDR 121 4 -1.12 (-1.94 to -0.27) 1.50 (1 to 4) 
TF-CBT 753 13 -0.73 (-1.23 to -0.25) 2.47 (1 to 4) 
Psychoeducation 183 3 -0.51 (-1.47 to 0.44) 3.46 (1 to 6) 
non-TF-CBT 123 4 -0.43 (-1.35 to 0.53) 3.80 (1 to 6) 
IPT 32 1 -0.39 (-1.76 to 0.97)  
Counselling 205 4 -0.30 (-1.12 to 0.53) 4.31 (2 to 6) 
Present-centered therapy 70 2 -0.15 (-1.29 to 1.01)  
Attention placebo 44 2 -0.02 (-1.35 to 1.33)  
Waitlist 496 14 Reference 5.46 (4 to 6) 
Family therapy 72 1 0.15 (-1.13 to 1.43)  
CrI: credible intervals; EMDR: eye movement desensitisation reprocessing; IPT: interpersonal psychotherapy; SMD: standardised mean 
difference; TF-CBT: trauma-focused cognitive behavioural therapy 
k: number of randomised controlled trials (RCTs) that assessed each intervention; N: number randomised to each treatment across RCTs 
Negative values indicate a better effect for the intervention compared with the reference treatment (waitlist). 
Only interventions tested on at least 100 people were considered in ranking. 





Table 3. Network meta-analysis of psychological treatments for PTSD in adults, remission at treatment endpoint: interventions, 
magnitude of evidence base and results 
Remission at treatment endpoint 
N total = 2,249; k total = 34; 76 study arms 
Intervention N k Mean LOR (95%CrI) vs waitlist Mean rank (95%CrI) 
Psychodynamic therapy 49 1 4.61 (1.87 to 7.57)  
EMDR 132 5 3.38 (2.04 to 4.84) 1.17 (1 to 3) 
non-TF-CBT 65 2 3.30 (1.48 to 5.29)  
Relaxation 57 2 2.65 (0.77 to 4.59)  
IPT 72 2 2.53 (0.71 to 4.40)  
Present-centered therapy 75 2 2.50 (0.75 to 4.36)  
TF-CBT 601 21 2.46 (1.79 to 3.19) 2.15 (1 to 3) 
Couple intervention 49 2 2.14 (-0.51 to 4.83)  
Self-help with support 105 2 1.76 (0.03 to 3.49) 3.07 (1 to 4) 
TF-CBT + SSRI 57 1 1.65 (-0.61 to 4.00)  
Self-help without support 74 3 1.52 (-0.16 to 3.32)  
SSRI 87 2 1.42 (-0.45 to 3.42)  
Counselling 150 6 1.34 (0.20 to 2.51) 3.66 (3 to 4) 
Attention placebo 23 1 1.09 (-1.97 to 4.24)  
Psychoeducation 28 1 -0.75 (-4.66 to 3.07)  
Waitlist 625 23 Reference 4.97 (4 to 5) 
CrI: credible intervals; EMDR: eye movement desensitisation reprocessing; IPT: interpersonal psychotherapy; LOR: log-odds ratio; SSRI: 
selective serotonin reuptake inhibitor; TF-CBT: trauma-focused cognitive behavioural therapy 
k: number of randomised controlled trials (RCTs) that assessed each intervention; N: number randomised to each treatment across RCTs 
Positive values indicate a better effect for the intervention compared with the reference treatment (waitlist). 
Only interventions tested on at least 100 people were considered in ranking. 
In bold effects where the 95%CrI do not cross the line of no effect (LOR=0) 
 
